arrow
M

Michael R. Verneris

children's hospital colorado
H指数:67
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL

HLH样综合征与儿童B-ALL患者CAR T治疗后死亡风险增加及CD19阴性复发相关

2026-07-210
OA
Feasibility and safety of a novel CD19-directed CAR T-cell therapy in patients with R/R B-cell non-Hodgkin lymphoma

一种新型CD19靶向CAR T细胞疗法在复发/难治性B细胞非霍奇金淋巴瘤患者中的可行性与安全性

2026-06-030
PRE
Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults

采集时外周血 blasts 作为 tisagenlecleucel 治疗后儿童和年轻患者生存的风险因素

2026-01-010
OAAI
Opportunities and Challenges with CAR T-cell Treatment of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations from the Westhafen Intercontinental Group

CAR T细胞治疗儿童和年轻成人B细胞急性淋巴细胞白血病的机遇与挑战:Westhafen Intercontinental Group的综述与建议

2025-10-300
OAAI
Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

放宽接受Tisagenlecleucel治疗的低负担B-ALL儿童/青年患者的医院邻近要求

2025-10-030
OAAI
Harmonized Immune Recovery Monitoring after HCT: Evidence & Practical Guidance from the Westhafen Intercontinental Group

异基因造血干细胞移植后免疫重建监测的标准化:Westhafen Intercontinental Group的证据与实践指南

2025-09-050
OAAI
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel

儿科患者接受tisagenlecuecel治疗时血液毒性的表征与预测

2025-07-230
OAAI
A Randomized Clinical Trial Evaluating Lactiplantibacillus Plantarum for the Prevention of GI aGvHD: A Report From the Children’s Oncology Group (ACCL1633)

一项评估植物乳杆菌 Lactiplantibacillus plantarum 预防GI aGvHD的随机临床试验:来自儿童肿瘤组(ACCL1633)的报告

2025-07-010
PRE
Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

B细胞恢复在复发风险和CD19表型中的作用:tisagenlecleucel用于儿童B淋巴细胞急性白血病真实世界应用的多机构回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment
2024-04-183
OAAI
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
2024-02-082
OAAI
Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia

患有b细胞急性淋巴细胞白血病的儿童和年轻人在Tisagenlecleucel后进行巩固造血干细胞移植的实践偏好

2024-01-012
OAAI